Express Pharma

J&J to bring COVID-19 vaccine to India in partnership with Biological E 

Biological E has said it can produce 600 million doses for J&J and more than one billion doses a year of its own vaccine, developed with Baylor College of Medicine and Dynavax Technologies Corp

0 2,166

Johnson & Johnson is in talks with Biological E to possibly run local trials for its COVID-19 shot and manufacture it in India, a source told Reuters.

A senior government official earlier told that J&J was interested in manufacturing its vaccine in India.

The source, who asked not to be named as the talks were confidential, said a deal was not final but that Biological E had the capacity to expand its existing partnership with J&J.

Asked about J&J’s interest in India and if it was looking for a local partner like other foreign vaccine makers have, a J&J spokesman pointed Reuters to a prior agreement it had announced with Biological E in August.

At the time, J&J unit Janssen Pharmaceutica struck a preliminary deal with Biological E to collaborate on vaccines.

Biological E, whose own vaccine candidate developed with Baylor College of Medicine in Houston and US-based Dynavax Technologies Corp, is undergoing clinical trials in India, with late-stage testing due to begin in April, has said it can produce more than one billion vaccine doses a year.

“We are targeting 600 million doses for J&J,” Biological E’s Mahima Datla said, adding it was not clear when they could start production. “This will be in addition to our own produ